IRESSA 250 (Iressa 250 mg)
Generic Name: gefitinib
Pill with imprint IRESSA 250 is Brown, Round and has been identified as Iressa 250 mg. It is supplied by AstraZeneca Pharmaceuticals.
Iressa is used in the treatment of non-small cell lung cancer and belongs to the drug class EGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Iressa 250 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for IRESSA 250
Iressa
- Generic Name
- gefitinib
- Imprint
- IRESSA 250
- Strength
- 250 mg
- Color
- Brown
- Size
- 11.00 mm
- Shape
- Round
- Availability
- Prescription only
- Drug Class
- Egfr inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- AstraZeneca Pharmaceuticals
- National Drug Code (NDC)
- 00310-0482
- Inactive Ingredients
-
lactose monohydrate,
microcrystalline cellulose,
croscarmellose sodium,
povidone,
sodium lauryl sulfate,
magnesium stearate,
hypromelloses,
polyethylene glycol 300,
titanium dioxide,
ferric oxide red,
ferric oxide yellow
Note: Inactive ingredients may vary.
More about Iressa (gefitinib)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- 8 Reviews
- Drug class: EGFR inhibitors
- FDA Alerts (1)
- FDA Approval History
Consumer resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.